Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dyspnoea is the uncomfortable shortness of breath that debilitates millions of patients with lung disease, heart failure and cancer. It is often very difficult to treat. The sensations of dyspnoea are processed in the brain, and we believe that psychological factors modify and amplify these sensations, frequently exacerbating symptoms.

This study aims to identify the importance of learning in the brain mechanisms of dyspnoea by investigating a cohort of patients with chronic breathlessness undergoing pulmonary rehabilitation . Pulmonary rehabilitation is a six-week course of exercise, education and group therapy that improves dyspnoea but does not improve lung function. This leads us to hypothesise that some of the beneficial effects of PR maybe due to changes in brain processing, potentially relating to a learning effect.

Therefore to probe whether learning is important in the beneficial effects of pulmonary rehabilitation, we intend to modify learning with the drug d-cycloserine. D-cycloserine is an antibiotic that enhances learning due to its effects at N-methyl D-aspartate (NMDA) receptors in the hippocampus. Our previous study in a similar group of patients demonstrated the importance of the hippocampus in breathlessness perception, and we now wish to investigate this in more depth.

The study involves collecting physiological, psychological and clinical measures on in conjunction with brain scanning, before, during and once after pulmonary rehabilitation. Subjects will either receive d-cyloserine or placebo before the first four pulmonary rehabilitation sessions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)

NCT01219946

Chronic Obstructive Pulmonary Disease

COMPLETED

BRAIN, Symptoms, and Physical Activity in COPD

NCT04291131

COPD Chronic Musculoskeletal Pain

COMPLETED

Identification of Respiratory Profiles From Nasal Pressure Signals

NCT03753386

Healthy

COMPLETED NA

Assessment of Neuropsychiatric Function in Patients With Interstitial Lung Disease

NCT05719233

Lung Diseases, Interstitial

COMPLETED

Exploring Breathing Patterns

NCT04754490

COPD

SUSPENDED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug: d-cycloserine or placebo

Other Names:

comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception

250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Other Names:

comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception

250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation

D-cycloserine

Placebo Comparator: Drug: d-cycloserine or placebo

Other Names:

comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception

250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation

Group Type ACTIVE_COMPARATOR

d-cycloserine

Intervention Type DRUG

250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

d-cycloserine

250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.

Intervention Type DRUG

placebo

Other Names:

comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception

250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception Placebo - identically matched to d-cycloserine containing carrier compound only

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females with chronic lung disease, aged between 45 and 85 years old who have been referred for pulmonary rehabilitation.
* The subject is able and willing to give fully informed consent.

Exclusion Criteria

Any of the commonly accepted contraindications to MRI scanning, for example, severe claustrophobia, presence of metallic implants, a pacemaker etc.

* Pregnancy. The risk to foetus of radiofrequency energy of the MRI scan is unknown.
* Inadequate understanding of verbal and written information in English, sufficient to complete an MRI safety screening.
* Unable to lie flat and still for 1/2 hour
* Requirements for oxygen therapy
* Significant cardiac, neurological, psychiatric or metabolic disease
* Contra-indications to d-cycloserine: Alcoholism, known hypersensitivity, severe renal failure
* Regular therapy with prescribed opioid analgesics
* Antidepressant therapy (this may alter hippocampal plasticity)
* Previous pulmonary rehabilitation (because the learning may be different on repeat pulmonary rehabilitation treatments)

Minimum Eligible Age

45 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes